These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2178078)

  • 1. Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.
    Jones RN; Croco JL; Barrett MS; Novick WJ; Erwin ME
    Diagn Microbiol Infect Dis; 1990; 13(5):371-3. PubMed ID: 2178078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
    Jones RN; Pfaller MA; Fuchs PC; Aldridge K; Allen SD; Gerlach EH
    Diagn Microbiol Infect Dis; 1989; 12(6):489-94. PubMed ID: 2560421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.
    Sader HS; Rhomberg PR; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2011 May; 55(5):2390-4. PubMed ID: 21321149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
    Chemotherapy; 1990; 36(3):215-21. PubMed ID: 2159865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
    Venezia RA; Yocum DM; Robbiano EM; Echols RM
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefazolin and two beta-lactamase inhibitors, clavulanic acid and sulbactam, against Bacteroides fragilis.
    Fekete T; McGowen J; Cundy KR
    Antimicrob Agents Chemother; 1987 Feb; 31(2):321-2. PubMed ID: 3032097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
    Downes J; Andrew JH
    Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.
    Nishida K; Kunugita C; Uji T; Higashitani F; Hyodo A; Unemi N; Maiti SN; Phillips OA; Spevak P; Atchison KP; Salama SM; Atwal H; Micetich RG
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1895-900. PubMed ID: 10428909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
    Stearne LE; van Boxtel D; Lemmens N; Goessens WH; Mouton JW; Gyssens IC
    Antimicrob Agents Chemother; 2004 May; 48(5):1688-98. PubMed ID: 15105122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.
    Schaumann R; Funke M; Janssen E; Rodloff AC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3413-6. PubMed ID: 22430962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tazobactam prevention of emergence of resistance.
    Neu HC; Niu WW; Chin NX
    Diagn Microbiol Infect Dis; 1989; 12(6):477-80. PubMed ID: 2560419
    [No Abstract]   [Full Text] [Related]  

  • 19. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
    Snydman DR; Jacobus NV; McDermott LA; Goldstein EJ; Harrell L; Jenkins SG; Newton D; Patel R; Hecht DW
    Anaerobe; 2017 Feb; 43():21-26. PubMed ID: 27867083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic activity of cefsulodin combined with cefoxitin and sulbactam against Bacteroides species.
    Fu KP; Kimble EF; Zoganas H; Konopka EA
    J Antimicrob Chemother; 1984 Mar; 13(3):257-65. PubMed ID: 6327598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.